Search Results
Results found for "Ono Pharmaceutical"
Posts (82)
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for ...
April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery "Apr.19.2022 Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company and Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization
Other Pages (35)
- Dr. Evi Kostenis | Dr. GPCR Ecosystem
Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical
- A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice
Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral
- Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem
Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral
